18:50:06 EST Mon 16 Nov 2026
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Tempramed Technologies Ltd
Symbol VIVI
Shares Issued 80,668,136
Close 2026-11-16 C$ 0.33
Market Cap C$ 26,620,485
Recent Sedar+ Documents

Tempramed enters distribution deal in Qatar

2026-11-16 17:30 ET - News Release

Mr. Ron Nagar reports

TEMPRAMED SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT WITH DAYMED QATAR, EXPANDING GULF REGION COMMERCIAL FOOTPRINT

Tempramed Technologies Ltd. has entered into a definitive exclusive distribution agreement dated Nov. 7, 2026, with DayMed Trading for commercialization of Tempramed's medication temperature-protection products in the state of Qatar.

Under the distribution agreement, with a three-year commercial opportunity of approximately $500,000 (U.S.), DayMed will serve as Tempramed's exclusive distributor in Qatar for the company's products. The initial focus is Vivi Cap, Tempramed's reusable, passive temperature-protection solution for insulin pens with further expansion to include Vivi Cap Smart and Vivi Med as potential products within the distribution framework.

"Our agreement with DayMed is another meaningful step in building a scalable international distribution network through partners who understand their local health care systems," said Ron Nagar, chief executive officer and founder of Tempramed. "Qatar presents a compelling combination of high diabetes prevalence, increasing attention to metabolic health and a climate in which patients must take particular care to protect temperature-sensitive medications during day-to-day life.

"The approximately half-million-dollar potential under the initial agreement is an important commercial opportunity, but the strategic value goes beyond the contractual purchase volumes," added Mr. Nagar. "DayMed's relationships with hospitals and pharmacy chains can help bring Vivi Cap closer to patients at the point of prescription and dispensing. We believe this model can support long-term growth as Tempramed expands through health care and pharmacy channels across the Gulf region."

Qatar market opportunity for medication temperature protection

According to the IDF Diabetes Atlas, approximately 409,300 adults aged 20 to 79 were living with diabetes in Qatar in 2024, with an age-standardized diabetes prevalence of 24.6 per cent -- among the highest rates globally. These estimates reflect the substantial population potentially requiring long-term diabetes care, including patients prescribed injectable insulin therapies.

Obesity and related metabolic conditions reinforce the relevance of injectable therapy support. A peer-reviewed analysis of Qatar's 2023 STEPwise survey, published in BMJ Open in October, 2026, reported obesity among 37.8 per cent of surveyed adults aged 18 to 69 and overweight among another 36.4 per cent. While these figures do not measure GLP-1 prescriptions or Tempramed's directly addressable customer base, they provide independent context for the growing importance of metabolic health and treatment support solutions.

Qatar's government communications office describes the country's summers as hot and humid, with temperatures ranging from 25 C to 46 C. Such conditions make appropriate handling of temperature-sensitive medicines particularly important during commuting, travel, outdoor activities and transport from pharmacy to home. Tempramed's solutions are designed to provide practical thermal protection during permitted in-use conditions while users must continue to follow each medication manufacturer's labelled storage instructions.

About Tempramed Technologies Ltd.

Tempramed is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, Food and Drug Administration-registered thermal insulation devices that operate continuously without batteries or external power. Its commercial product portfolio includes Vivi Cap, Vivi Cap Smart, Vivi Epi and Vivi Med. Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, any time.

We seek Safe Harbor.

© 2026 Canjex Publishing Ltd. All rights reserved.